Pathogenic Variants of the PHEX Gene
Abstract
:1. Introduction
2. Pathogenic Variants of the PHEX Gene
2.1. Mosaicism
2.2. Splice Site Variants
2.3. Nonsense Mediated mRNA Decay (NMD)
2.4. c.*231A>G Variant
3. Functional Analysis Based on Pathogenic Variants Associated with XLH
4. Genotype–Phenotype Relationship
4.1. Gene Dosage Effect
4.2. Location of Pathogenic Variant
4.3. Truncating and Non-Truncating Variants
4.4. Preservation of Zinc-Binding Sites in Mutant PHEX
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Read, A.P.; Thakker, R.V.; Davies, K.E.; Mountford, R.C.; Brenton, D.P.; Davies, M.; Glorieux, F.; Harris, R.; Hendy, G.N.; King, A.; et al. Mapping of human X-linked hypophosphataemic rickets by multilocus linkage analysis. Hum. Genet. 1986, 73, 267–270. [Google Scholar] [CrossRef]
- Consortium, T.H. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium. Nat. Genet. 1995, 11, 130–136. [Google Scholar]
- Carpinelli, M.R.; Wicks, I.P.; Sims, N.A.; O’Donnell, K.; Hanzinikolas, K.; Burt, R.; Foote, S.J.; Bahlo, M.; Alexander, W.S.; Hilton, D.J. An ethyl-nitrosourea-induced point mutation in phex causes exon skipping, x-linked hypophosphatemia, and rickets. Am. J. Pathol. 2002, 161, 1925–1933. [Google Scholar] [CrossRef] [Green Version]
- Eicher, E.M.; Southard, J.L.; Scriver, C.R.; Glorieux, F.H. Hypophosphatemia: Mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc. Natl. Acad. Sci. USA 1976, 73, 4667–4671. [Google Scholar] [CrossRef] [Green Version]
- Strom, T.M.; Francis, F.; Lorenz, B.; Boddrich, A.; Econs, M.J.; Lehrach, H.; Meitinger, T. Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum. Mol. Genet. 1997, 6, 165–171. [Google Scholar] [CrossRef] [Green Version]
- Carpenter, T.O.; Imel, E.A.; Holm, I.A.; Jan de Beur, S.M.; Insogna, K.L. A clinician’s guide to X-linked hypophosphatemia. J. Bone Miner. Res. 2011, 26, 1381–1388. [Google Scholar] [CrossRef] [Green Version]
- Sabbagh, Y.; Jones, A.O.; Tenenhouse, H.S. PHEXdb, a locus-specific database for mutations causing X-linked hypophosphatemia. Hum. Mutat. 2000, 16, 1–6. [Google Scholar] [CrossRef]
- Rush, E.T.; Johnson, B.; Aradhya, S.; Beltran, D.; Bristow, S.L.; Eisenbeis, S.; Guerra, N.E.; Krolczyk, S.; Miller, N.; Morales, A.; et al. Molecular Diagnoses of X-Linked and Other Genetic Hypophosphatemias: Results From a Sponsored Genetic Testing Program. J. Bone Miner. Res. 2022, 37, 202–214. [Google Scholar] [CrossRef]
- Sarafrazi, S.; Daugherty, S.C.; Miller, N.; Boada, P.; Carpenter, T.O.; Chunn, L.; Dill, K.; Econs, M.J.; Eisenbeis, S.; Imel, E.A.; et al. Novel PHEX gene locus-specific database: Comprehensive characterization of vast number of variants associated with X-linked hypophosphatemia (XLH). Hum. Mutat. 2022, 43, 143–157. [Google Scholar] [CrossRef]
- Jonsson, K.B.; Zahradnik, R.; Larsson, T.; White, K.E.; Sugimoto, T.; Imanishi, Y.; Yamamoto, T.; Hampson, G.; Koshiyama, H.; Ljunggren, O.; et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 2003, 348, 1656–1663. [Google Scholar] [CrossRef]
- Shimada, T.; Mizutani, S.; Muto, T.; Yoneya, T.; Hino, R.; Takeda, S.; Takeuchi, Y.; Fujita, T.; Fukumoto, S.; Yamashita, T. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. USA 2001, 98, 6500–6505. [Google Scholar] [CrossRef] [Green Version]
- Fukumoto, S.; Yamashita, T. FGF23 is a hormone-regulating phosphate metabolism--unique biological characteristics of FGF23. Bone 2007, 40, 1190–1195. [Google Scholar] [CrossRef]
- Shimada, T.; Hasegawa, H.; Yamazaki, Y.; Muto, T.; Hino, R.; Takeuchi, Y.; Fujita, T.; Nakahara, K.; Fukumoto, S.; Yamashita, T. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 2004, 19, 429–435. [Google Scholar] [CrossRef] [Green Version]
- Lorenz-Depiereux, B.; Bastepe, M.; Benet-Pages, A.; Amyere, M.; Wagenstaller, J.; Muller-Barth, U.; Badenhoop, K.; Kaiser, S.M.; Rittmaster, R.S.; Shlossberg, A.H.; et al. DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat. Genet. 2006, 38, 1248–1250. [Google Scholar] [CrossRef]
- Feng, J.Q.; Ward, L.M.; Liu, S.; Lu, Y.; Xie, Y.; Yuan, B.; Yu, X.; Rauch, F.; Davis, S.I.; Zhang, S.; et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 2006, 38, 1310–1315. [Google Scholar] [CrossRef]
- Consortium, T.A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 2000, 26, 345–348. [Google Scholar]
- Lorenz-Depiereux, B.; Schnabel, D.; Tiosano, D.; Hausler, G.; Strom, T.M. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am. J. Hum. Genet. 2010, 86, 267–272. [Google Scholar] [CrossRef] [Green Version]
- Levy-Litan, V.; Hershkovitz, E.; Avizov, L.; Leventhal, N.; Bercovich, D.; Chalifa-Caspi, V.; Manor, E.; Buriakovsky, S.; Hadad, Y.; Goding, J.; et al. Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am. J. Hum. Genet. 2010, 86, 273–278. [Google Scholar] [CrossRef] [Green Version]
- Simpson, M.A.; Hsu, R.; Keir, L.S.; Hao, J.; Sivapalan, G.; Ernst, L.M.; Zackai, E.H.; Al-Gazali, L.I.; Hulskamp, G.; Kingston, H.M.; et al. Mutations in FAM20C are associated with lethal osteosclerotic bone dysplasia (Raine syndrome), highlighting a crucial molecule in bone development. Am. J. Hum. Genet. 2007, 81, 906–912. [Google Scholar] [CrossRef] [Green Version]
- Rowe, P.S.; Garrett, I.R.; Schwarz, P.M.; Carnes, D.L.; Lafer, E.M.; Mundy, G.R.; Gutierrez, G.E. Surface plasmon resonance (SPR) confirms that MEPE binds to PHEX via the MEPE-ASARM motif: A model for impaired mineralization in X-linked rickets (HYP). Bone 2005, 36, 33–46. [Google Scholar] [CrossRef] [Green Version]
- Martin, A.; David, V.; Laurence, J.S.; Schwarz, P.M.; Lafer, E.M.; Hedge, A.M.; Rowe, P.S. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008, 149, 1757–1772. [Google Scholar] [CrossRef] [Green Version]
- Liu, S.; Zhou, J.; Tang, W.; Jiang, X.; Rowe, D.W.; Quarles, L.D. Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab. 2006, 291, E38–E49. [Google Scholar] [CrossRef]
- Miao, D.; Bai, X.; Panda, D.; McKee, M.; Karaplis, A.; Goltzman, D. Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition. Endocrinology 2001, 142, 926–939. [Google Scholar] [CrossRef]
- Sitara, D.; Razzaque, M.S.; Hesse, M.; Yoganathan, S.; Taguchi, T.; Erben, R.G.; Juppner, H.; Lanske, B. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004, 23, 421–432. [Google Scholar] [CrossRef] [Green Version]
- Beck, L.; Soumounou, Y.; Martel, J.; Krishnamurthy, G.; Gauthier, C.; Goodyer, C.G.; Tenenhouse, H.S. Pex/PEX tissue distribution and evidence for a deletion in the 3′ region of the Pex gene in X-linked hypophosphatemic mice. J. Clin. Investig. 1997, 99, 1200–1209. [Google Scholar] [CrossRef] [Green Version]
- Bowe, A.E.; Finnegan, R.; Jan de Beur, S.M.; Cho, J.; Levine, M.A.; Kumar, R.; Schiavi, S.C. FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem. Biophys. Res. Commun. 2001, 284, 977–981. [Google Scholar] [CrossRef]
- Benet-Pages, A.; Lorenz-Depiereux, B.; Zischka, H.; White, K.E.; Econs, M.J.; Strom, T.M. FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004, 35, 455–462. [Google Scholar] [CrossRef]
- Guo, R.; Liu, S.; Spurney, R.F.; Quarles, L.D. Analysis of recombinant Phex: An endopeptidase in search of a substrate. Am. J. Physiol. Endocrinol. Metab. 2001, 281, E837–E847. [Google Scholar] [CrossRef] [Green Version]
- Liu, S.; Guo, R.; Simpson, L.G.; Xiao, Z.S.; Burnham, C.E.; Quarles, L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J. Biol. Chem. 2003, 278, 37419–37426. [Google Scholar] [CrossRef] [Green Version]
- Rowe, P.S.; Oudet, C.L.; Francis, F.; Sinding, C.; Pannetier, S.; Econs, M.J.; Strom, T.M.; Meitinger, T.; Garabedian, M.; David, A.; et al. Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). Hum. Mol. Genet. 1997, 6, 539–549. [Google Scholar] [CrossRef] [Green Version]
- Francis, F.; Strom, T.M.; Hennig, S.; Boddrich, A.; Lorenz, B.; Brandau, O.; Mohnike, K.L.; Cagnoli, M.; Steffens, C.; Klages, S.; et al. Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets. Genome. Res. 1997, 7, 573–585. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Holm, I.A.; Huang, X.; Kunkel, L.M. Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets. Am. J. Hum. Genet. 1997, 60, 790–797. [Google Scholar] [PubMed]
- Dixon, P.H.; Christie, P.T.; Wooding, C.; Trump, D.; Grieff, M.; Holm, I.; Gertner, J.M.; Schmidtke, J.; Shah, B.; Shaw, N.; et al. Mutational analysis of PHEX gene in X-linked hypophosphatemia. J. Clin. Endocrinol. Metab. 1998, 83, 3615–3623. [Google Scholar] [CrossRef]
- Filisetti, D.; Ostermann, G.; von Bredow, M.; Strom, T.; Filler, G.; Ehrich, J.; Pannetier, S.; Garnier, J.M.; Rowe, P.; Francis, F.; et al. Non-random distribution of mutations in the PHEX gene, and under-detected missense mutations at non-conserved residues. Eur. J. Hum. Genet. 1999, 7, 615–619. [Google Scholar] [CrossRef]
- Tyynismaa, H.; Kaitila, I.; Nanto-Salonen, K.; Ala-Houhala, M.; Alitalo, T. Identification of fifteen novel PHEX gene mutations in Finnish patients with hypophosphatemic rickets. Hum. Mutat. 2000, 15, 383–384. [Google Scholar] [CrossRef]
- Popowska, E.; Pronicka, E.; Sulek, A.; Jurkiewicz, D.; Rowe, P.; Rowinska, E.; Krajewska-Walasek, M. X-linked hypophosphatemia in Polish patients. 1. Mutations in the PHEX gene. J. Appl. Genet. 2000, 41, 293–302. [Google Scholar]
- Holm, I.A.; Nelson, A.E.; Robinson, B.G.; Mason, R.S.; Marsh, D.J.; Cowell, C.T.; Carpenter, T.O. Mutational analysis and genotype-phenotype correlation of the PHEX gene in X-linked hypophosphatemic rickets. J. Clin. Endocrinol. Metab. 2001, 86, 3889–3899. [Google Scholar] [CrossRef]
- Christie, P.T.; Harding, B.; Nesbit, M.A.; Whyte, M.P.; Thakker, R.V. X-linked hypophosphatemia attributable to pseudoexons of the PHEX gene. J. Clin. Endocrinol. Metab. 2001, 86, 3840–3844. [Google Scholar] [CrossRef]
- Cho, H.Y.; Lee, B.H.; Kang, J.H.; Ha, I.S.; Cheong, H.I.; Choi, Y. A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr. Res. 2005, 58, 329–333. [Google Scholar] [CrossRef] [Green Version]
- Song, H.R.; Park, J.W.; Cho, D.Y.; Yang, J.H.; Yoon, H.R.; Jung, S.C. PHEX gene mutations and genotype-phenotype analysis of Korean patients with hypophosphatemic rickets. J. Korean Med. Sci. 2007, 22, 981–986. [Google Scholar] [CrossRef] [Green Version]
- Ichikawa, S.; Traxler, E.A.; Estwick, S.A.; Curry, L.R.; Johnson, M.L.; Sorenson, A.H.; Imel, E.A.; Econs, M.J. Mutational survey of the PHEX gene in patients with X-linked hypophosphatemic rickets. Bone 2008, 43, 663–666. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gaucher, C.; Walrant-Debray, O.; Nguyen, T.M.; Esterle, L.; Garabedian, M.; Jehan, F. PHEX analysis in 118 pedigrees reveals new genetic clues in hypophosphatemic rickets. Hum. Genet. 2009, 125, 401–411. [Google Scholar] [CrossRef] [PubMed]
- Clausmeyer, S.; Hesse, V.; Clemens, P.C.; Engelbach, M.; Kreuzer, M.; Becker-Rose, P.; Spital, H.; Schulze, E.; Raue, F. Mutational analysis of the PHEX gene: Novel point mutations and detection of large deletions by MLPA in patients with X-linked hypophosphatemic rickets. Calcif. Tissue Int. 2009, 85, 211–220. [Google Scholar] [CrossRef] [PubMed]
- Morey, M.; Castro-Feijoo, L.; Barreiro, J.; Cabanas, P.; Pombo, M.; Gil, M.; Bernabeu, I.; Diaz-Grande, J.M.; Rey-Cordo, L.; Ariceta, G.; et al. Genetic diagnosis of X-linked dominant Hypophosphatemic Rickets in a cohort study: Tubular reabsorption of phosphate and 1,25(OH)2D serum levels are associated with PHEX mutation type. BMC Med. Genet. 2011, 12, 116. [Google Scholar] [CrossRef] [Green Version]
- Ruppe, M.D.; Brosnan, P.G.; Au, K.S.; Tran, P.X.; Dominguez, B.W.; Northrup, H. Mutational analysis of PHEX, FGF23 and DMP1 in a cohort of patients with hypophosphatemic rickets. Clin. Endocrinol. 2011, 74, 312–318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jap, T.S.; Chiu, C.Y.; Niu, D.M.; Levine, M.A. Three novel mutations in the PHEX gene in Chinese subjects with hypophosphatemic rickets extends genotypic variability. Calcif. Tissue Int. 2011, 88, 370–377. [Google Scholar] [CrossRef] [Green Version]
- Quinlan, C.; Guegan, K.; Offiah, A.; Neill, R.O.; Hiorns, M.P.; Ellard, S.; Bockenhauer, D.; Hoff, W.V.; Waters, A.M. Growth in PHEX-associated X-linked hypophosphatemic rickets: The importance of early treatment. Pediatr. Nephrol. 2012, 27, 581–588. [Google Scholar] [CrossRef]
- Beck-Nielsen, S.S.; Brixen, K.; Gram, J.; Brusgaard, K. Mutational analysis of PHEX, FGF23, DMP1, SLC34A3 and CLCN5 in patients with hypophosphatemic rickets. J. Hum. Genet. 2012, 57, 453–458. [Google Scholar] [CrossRef]
- Kinoshita, Y.; Saito, T.; Shimizu, Y.; Hori, M.; Taguchi, M.; Igarashi, T.; Fukumoto, S.; Fujita, T. Mutational analysis of patients with FGF23-related hypophosphatemic rickets. Eur. J. Endocrinol. 2012, 167, 165–172. [Google Scholar] [CrossRef] [Green Version]
- Lee, S.H.; Agashe, M.V.; Suh, S.W.; Yoon, Y.C.; Song, S.H.; Yang, J.H.; Lee, H.; Song, H.R. Paravertebral ligament ossification in vitamin D-resistant rickets: Incidence, clinical significance, and genetic evaluation. Spine 2012, 37, E792–E796. [Google Scholar] [CrossRef]
- Durmaz, E.; Zou, M.; Al-Rijjal, R.A.; Baitei, E.Y.; Hammami, S.; Bircan, I.; Akcurin, S.; Meyer, B.; Shi, Y. Novel and de novo PHEX mutations in patients with hypophosphatemic rickets. Bone 2013, 52, 286–291. [Google Scholar] [CrossRef] [PubMed]
- Yue, H.; Yu, J.B.; He, J.W.; Zhang, Z.; Fu, W.Z.; Zhang, H.; Wang, C.; Hu, W.W.; Gu, J.M.; Hu, Y.Q.; et al. Identification of two novel mutations in the PHEX gene in Chinese patients with hypophosphatemic rickets/osteomalacia. PLoS ONE 2014, 9, e97830. [Google Scholar] [CrossRef] [PubMed]
- Capelli, S.; Donghi, V.; Maruca, K.; Vezzoli, G.; Corbetta, S.; Brandi, M.L.; Mora, S.; Weber, G. Clinical and molecular heterogeneity in a large series of patients with hypophosphatemic rickets. Bone 2015, 79, 143–149. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Yang, R.; Wang, Y.; Ye, J.; Han, L.; Qiu, W.; Gu, X. A pilot study of gene testing of genetic bone dysplasia using targeted next-generation sequencing. J. Hum. Genet. 2015, 60, 769–776. [Google Scholar] [CrossRef] [PubMed]
- Rafaelsen, S.; Johansson, S.; Raeder, H.; Bjerknes, R. Hereditary hypophosphatemia in Norway: A retrospective population-based study of genotypes, phenotypes, and treatment complications. Eur. J. Endocrinol. 2016, 174, 125–136. [Google Scholar] [CrossRef] [Green Version]
- Li, S.S.; Gu, J.M.; Yu, W.J.; He, J.W.; Fu, W.Z.; Zhang, Z.L. Seven novel and six de novo PHEX gene mutations in patients with hypophosphatemic rickets. Int. J. Mol. Med. 2016, 38, 1703–1714. [Google Scholar] [CrossRef] [Green Version]
- Guven, A.; Al-Rijjal, R.A.; BinEssa, H.A.; Dogan, D.; Kor, Y.; Zou, M.; Kaya, N.; Alenezi, A.F.; Hancili, S.; Tarim, O.; et al. Mutational analysis of PHEX, FGF23 and CLCN5 in patients with hypophosphataemic rickets. Clin. Endocrinol. 2017, 87, 103–112. [Google Scholar] [CrossRef]
- Acar, S.; BinEssa, H.A.; Demir, K.; Al-Rijjal, R.A.; Zou, M.; Catli, G.; Anik, A.; Al-Enezi, A.F.; Ozisik, S.; Al-Faham, M.S.A.; et al. Clinical and genetic characteristics of 15 families with hereditary hypophosphatemia: Novel Mutations in PHEX and SLC34A3. PLoS ONE 2018, 13, e0193388. [Google Scholar] [CrossRef] [Green Version]
- Chesher, D.; Oddy, M.; Darbar, U.; Sayal, P.; Casey, A.; Ryan, A.; Sechi, A.; Simister, C.; Waters, A.; Wedatilake, Y.; et al. Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations. J. Inherit. Metab. Dis. 2018, 41, 865–876. [Google Scholar] [CrossRef] [Green Version]
- Gu, J.; Wang, C.; Zhang, H.; Yue, H.; Hu, W.; He, J.; Fu, W.; Zhang, Z. Targeted resequencing of phosphorus metabolismrelated genes in 86 patients with hypophosphatemic rickets/osteomalacia. Int. J. Mol. Med. 2018, 42, 1603–1614. [Google Scholar]
- Marik, B.; Bagga, A.; Sinha, A.; Hari, P.; Sharma, A. Genetics of Refractory Rickets: Identification of Novel PHEX Mutations in Indian Patients and a Literature Update. J. Pediatr. Genet. 2018, 7, 47–59. [Google Scholar] [CrossRef]
- Hernandez-Frias, O.; Gil-Pena, H.; Perez-Roldan, J.M.; Gonzalez-Sanchez, S.; Ariceta, G.; Chocron, S.; Loza, R.; de la Cerda Ojeda, F.; Madariaga, L.; Vergara, I.; et al. Risk of cardiovascular involvement in pediatric patients with X-linked hypophosphatemia. Pediatr. Nephrol. 2019, 34, 1077–1086. [Google Scholar] [CrossRef] [PubMed]
- Zhang, C.; Zhao, Z.; Sun, Y.; Xu, L.; JiaJue, R.; Cui, L.; Pang, Q.; Jiang, Y.; Li, M.; Wang, O.; et al. Clinical and genetic analysis in a large Chinese cohort of patients with X-linked hypophosphatemia. Bone 2019, 121, 212–220. [Google Scholar] [CrossRef] [PubMed]
- Lin, Y.; Xu, J.; Li, X.; Sheng, H.; Su, L.; Wu, M.; Cheng, J.; Huang, Y.; Mao, X.; Zhou, Z.; et al. Novel variants and uncommon cases among southern Chinese children with X-linked hypophosphatemia. J. Endocrinol. Investig. 2020, 43, 1577–1590. [Google Scholar] [CrossRef] [PubMed]
- Zheng, B.; Wang, C.; Chen, Q.; Che, R.; Sha, Y.; Zhao, F.; Ding, G.; Zhou, W.; Jia, Z.; Huang, S.; et al. Functional Characterization of PHEX Gene Variants in Children With X-Linked Hypophosphatemic Rickets Shows No Evidence of Genotype-Phenotype Correlation. J. Bone Miner. Res. 2020, 35, 1718–1725. [Google Scholar] [CrossRef] [PubMed]
- Baroncelli, G.I.; Zampollo, E.; Manca, M.; Toschi, B.; Bertelloni, S.; Michelucci, A.; Isola, A.; Bulleri, A.; Peroni, D.; Giuca, M.R. Pulp chamber features, prevalence of abscesses, disease severity, and PHEX mutation in X-linked hypophosphatemic rickets. J. Bone Miner. Metab. 2021, 39, 212–223. [Google Scholar] [CrossRef]
- Ishihara, Y.; Ohata, Y.; Takeyari, S.; Kitaoka, T.; Fujiwara, M.; Nakano, Y.; Yamamoto, K.; Yamada, C.; Yamamoto, K.; Michigami, T.; et al. Genotype-phenotype analysis, and assessment of the importance of the zinc-binding site in PHEX in Japanese patients with X-linked hypophosphatemic rickets using 3D structure modeling. Bone 2021, 153, 116135. [Google Scholar] [CrossRef]
- Jimenez, M.; Ivanovic-Zuvic, D.; Loureiro, C.; Carvajal, C.A.; Cavada, G.; Schneider, P.; Gallardo, E.; Garcia, C.; Gonzalez, G.; Contreras, O.; et al. Clinical and molecular characterization of Chilean patients with X-linked hypophosphatemia. Osteoporos. Int. 2021, 32, 1825–1836. [Google Scholar] [CrossRef]
- Lin, X.; Li, S.; Zhang, Z.; Yue, H. Clinical and Genetic Characteristics of 153 Chinese Patients With X-Linked Hypophosphatemia. Front. Cell Dev. Biol. 2021, 9, 617738. [Google Scholar] [CrossRef]
- Park, P.G.; Lim, S.H.; Lee, H.; Ahn, Y.H.; Cheong, H.I.; Kang, H.G. Genotype and Phenotype Analysis in X-Linked Hypophosphatemia. Front Pediatr. 2021, 9, 699767. [Google Scholar] [CrossRef]
- Rodriguez-Rubio, E.; Gil-Pena, H.; Chocron, S.; Madariaga, L.; de la Cerda-Ojeda, F.; Fernandez-Fernandez, M.; de Lucas-Collantes, C.; Gil, M.; Luis-Yanes, M.I.; Vergara, I.; et al. Correction to: Phenotypic characterization of X-linked hypophosphatemia in pediatric Spanish population. Orphanet J Rare. Dis. 2021, 16, 154. [Google Scholar] [CrossRef]
- Jacobsen, C.; Shen, Y.; Holm, I. Approaches to Genetic Testing, 9th ed.; Bilezikian, J.P., American Society for Bone and Mineral Research, Eds.; Wiley Blackwell: New York, NY, USA, 2019. [Google Scholar]
- Ma, S.L.; Vega-Warner, V.; Gillies, C.; Sampson, M.G.; Kher, V.; Sethi, S.K.; Otto, E.A. Whole Exome Sequencing Reveals Novel PHEX Splice Site Mutations in Patients with Hypophosphatemic Rickets. PLoS ONE 2015, 10, e0130729. [Google Scholar] [CrossRef] [Green Version]
- Li, B.; Wang, X.; Hao, X.; Liu, Y.; Wang, Y.; Shan, C.; Ao, X.; Liu, Y.; Bao, H.; Li, P. A novel c.2179T>C mutation blocked the intracellular transport of PHEX protein and caused X-linked hypophosphatemic rickets in a Chinese family. Mol. Genet. Genom. Med. 2020, 8, e1262. [Google Scholar] [CrossRef] [PubMed]
- Lin, Y.; Cai, Y.; Xu, J.; Zeng, C.; Sheng, H.; Yu, Y.; Li, X.; Liu, L. ‘Isolated’ germline mosaicism in the phenotypically normal father of a girl with X-linked hypophosphatemic rickets. Eur. J. Endocrinol. 2020, 182, K1–K6. [Google Scholar] [CrossRef]
- Weng, C.; Chen, J.; Sun, L.; Zhou, Z.W.; Feng, X.; Sun, J.H.; Lu, L.P.; Yu, P.; Qi, M. A de novo mosaic mutation of PHEX in a boy with hypophosphatemic rickets. J. Hum. Genet. 2016, 61, 223–227. [Google Scholar] [CrossRef]
- Goji, K.; Ozaki, K.; Sadewa, A.H.; Nishio, H.; Matsuo, M. Somatic and germline mosaicism for a mutation of the PHEX gene can lead to genetic transmission of X-linked hypophosphatemic rickets that mimics an autosomal dominant trait. J. Clin. Endocrinol. Metab. 2006, 91, 365–370. [Google Scholar] [CrossRef] [PubMed]
- BinEssa, H.A.; Zou, M.; Al-Enezi, A.F.; Alomrani, B.; Al-Faham, M.S.A.; Al-Rijjal, R.A.; Meyer, B.F.; Shi, Y. Functional analysis of 22 splice-site mutations in the PHEX, the causative gene in X-linked dominant hypophosphatemic rickets. Bone 2019, 125, 186–193. [Google Scholar] [CrossRef]
- Zou, M.; Bulus, D.; Al-Rijjal, R.A.; Andiran, N.; BinEssa, H.; Kattan, W.E.; Meyer, B.; Shi, Y. Hypophosphatemic rickets caused by a novel splice donor site mutation and activation of two cryptic splice donor sites in the PHEX gene. J. Pediatr. Endocrinol. Metab. 2015, 28, 211–216. [Google Scholar] [CrossRef] [PubMed]
- Frischmeyer, P.A.; Dietz, H.C. Nonsense-mediated mRNA decay in health and disease. Hum. Mol. Genet. 1999, 8, 1893–1900. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mort, M.; Ivanov, D.; Cooper, D.N.; Chuzhanova, N.A. A meta-analysis of nonsense mutations causing human genetic disease. Hum. Mutat. 2008, 29, 1037–1047. [Google Scholar] [CrossRef] [PubMed]
- Kurosaki, T.; Popp, M.W.; Maquat, L.E. Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nat. Rev. Mol. Cell Biol. 2019, 20, 406–420. [Google Scholar] [CrossRef] [PubMed]
- Chang, Y.F.; Imam, J.S.; Wilkinson, M.F. The nonsense-mediated decay RNA surveillance pathway. Annu. Rev. Biochem. 2007, 76, 51–74. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, W.; Tan, L.; Li, X.; Zhang, X.; Wu, X.; Chen, H.; Hu, L.; Wang, X.; Luo, X.; Wang, F.; et al. Identification of a p.Trp403* nonsense variant in PHEX causing X-linked hypophosphatemia by inhibiting p38 MAPK signaling. Hum. Mutat. 2019, 40, 879–885. [Google Scholar] [CrossRef]
- Mumm, S.; Huskey, M.; Cajic, A.; Wollberg, V.; Zhang, F.; Madson, K.L.; Wenkert, D.; McAlister, W.H.; Gottesman, G.S.; Whyte, M.P. PHEX 3′-UTR c.*231A>G near the polyadenylation signal is a relatively common, mild, American mutation that masquerades as sporadic or X-linked recessive hypophosphatemic rickets. J. Bone Miner. Res. 2015, 30, 137–143. [Google Scholar] [CrossRef]
- Smith, P.S.; Gottesman, G.S.; Zhang, F.; Cook, F.; Ramirez, B.; Wenkert, D.; Wollberg, V.; Huskey, M.; Mumm, S.; Whyte, M.P. X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3′-UTR Mutation c.*231A>G (A Retrospective Case-Control Study). J. Bone Miner. Res. 2020, 35, 920–931. [Google Scholar] [CrossRef]
- Mumm, S.; Huskey, M.; Duan, S.; Wollberg, V.; Bijanki, V.; Gottesman, G.S.; Whyte, M.P.; Smith, P. (Eds.) X-Linked Hypophosphatemia: All Eight Individuals Representing Separate American Families Carrying the PHEX 3′UTR Mutation c.* 231A> G Tested Positive for an Exon 13-15 Duplication. In Journal of Bone and Mineral Research; Wiley: Hoboken, NJ, USA, 2019. [Google Scholar]
- Sabbagh, Y.; Boileau, G.; DesGroseillers, L.; Tenenhouse, H.S. Disease-causing missense mutations in the PHEX gene interfere with membrane targeting of the recombinant protein. Hum. Mol. Genet. 2001, 10, 1539–1546. [Google Scholar] [CrossRef] [Green Version]
- Lipman, M.L.; Panda, D.; Bennett, H.P.; Henderson, J.E.; Shane, E.; Shen, Y.; Goltzman, D.; Karaplis, A.C. Cloning of human PEX cDNA. Expression, subcellular localization, and endopeptidase activity. J. Biol. Chem. 1998, 273, 13729–13737. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015, 17, 405–424. [Google Scholar] [CrossRef] [Green Version]
- Nykamp, K.; Anderson, M.; Powers, M.; Garcia, J.; Herrera, B.; Ho, Y.Y.; Kobayashi, Y.; Patil, N.; Thusberg, J.; Westbrook, M.; et al. Sherloc: A comprehensive refinement of the ACMG-AMP variant classification criteria. Genet. Med. 2017, 19, 1105–1117. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Greenblatt, M.B.; Shim, J.H.; Glimcher, L.H. Mitogen-activated protein kinase pathways in osteoblasts. Annu. Rev. Cell Dev. Biol. 2013, 29, 63–79. [Google Scholar] [CrossRef] [PubMed]
- Hardy, D.C.; Murphy, W.A.; Siegel, B.A.; Reid, I.R.; Whyte, M.P. X-linked hypophosphatemia in adults: Prevalence of skeletal radiographic and scintigraphic features. Radiology 1989, 171, 403–414. [Google Scholar] [CrossRef]
- Whyte, M.P.; Schranck, F.W.; Armamento-Villareal, R. X-linked hypophosphatemia: A search for gender, race, anticipation, or parent of origin effects on disease expression in children. J. Clin. Endocrinol. Metab. 1996, 81, 4075–4080. [Google Scholar]
- Bianchetti, L.; Oudet, C.; Poch, O. M13 endopeptidases: New conserved motifs correlated with structure, and simultaneous phylogenetic occurrence of PHEX and the bony fish. Proteins 2002, 47, 481–488. [Google Scholar] [CrossRef]
- Turner, A.J.; Isaac, R.E.; Coates, D. The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function. Bioessays 2001, 23, 261–269. [Google Scholar] [CrossRef]
- Schiering, N.; D’Arcy, A.; Villard, F.; Ramage, P.; Logel, C.; Cumin, F.; Ksander, G.M.; Wiesmann, C.; Karki, R.G.; Mogi, M. Structure of neprilysin in complex with the active metabolite of sacubitril. Sci. Rep. 2016, 6, 27909. [Google Scholar] [CrossRef] [Green Version]
Author | Year | Probands | Variant Positive | Variant Positivity Rate (%) | Variants | Reference |
---|---|---|---|---|---|---|
Rowe | 1997 | 106 | NR | 83 | NR | [30] |
Francis | 1997 | 43 | 33 | 77 | 26 | [31] |
Holm | 1997 | 22 | 9 | 41 | 9 | [32] |
Dixon | 1998 | 68 | 31 | 46 | 31 | [33] |
Filisetti | 1999 | 22 | 22 | 100 | 22 | [34] |
Tyynismaa | 2000 | 20 | 19 | 95 | 18 | [35] |
Popowska | 2000 | 35 | 35 | 100 | 29 | [36] |
Holm | 2001 | 41 | 22 | 54 | 20 | [37] |
Christie | 2001 | 11 [a] | 1 | NA | NR | [38] |
Cho | 2005 | 17 | 8 | 47 | 7 | [39] |
Song | 2007 | 15 | 9 | 60 | 8 | [40] |
Ichikawa | 2008 | 26 | 26 | 100 | 18 | [41] |
Gaucher | 2009 | 118 | 93 | 79 | NR | [42] |
Clausmeyer | 2009 | 71 [b] | 37 | 52 | 28 | [43] |
Morey | 2011 | 36 | 36 | 100 | 34 | [44] |
Ruppe | 2011 | 46 | 27 | 59 | 27 | [45] |
Jap | 2011 | 9 | 5 | 56 | 5 | [46] |
Quinlan | 2012 | 46 | 38 | 83 | 24 | [47] |
Beck-Nielsen | 2012 | 24 | 21 | 88 | 20 | [48] |
Kinoshita | 2012 | 27 | 26 | 96 | 17 | [49] |
Lee | 2012 | 6 | 6 [c] | NA | 4 | [50] |
Durmaz | 2013 | 6 | 6 | 100 | 6 | [51] |
Yue | 2014 | 9 | 9 | 100 | 10 | [52] |
Capelli | 2015 | 26 | 22 | 84 | 19 | [53] |
Zhang | 2015 | 13 | 9 | 69 | 9 | [54] |
Rafaelsen | 2016 | 19 | 15 | 79 | 13 | [55] |
Li | 2016 | 18 | 18 | 100 | 17 | [56] |
Guven | 2017 | 9 | 7 | 78 | 7 | [57] |
Acar | 2018 | 15 | 12 | 80 | 12 | [58] |
Chesher | 2018 | 35 | 35 | 100 | 37 | [59] |
Gu | 2018 | 86 | 7 | NA | NR | [60] |
Marik | 2018 | 32 | 8 | 25 | NR | [61] |
Hernández-Frías | 2019 | 22 | 22 [c] | NA | NR | [62] |
Zhang | 2019 | 216 | 216 [c] | NA | 166 | [63] |
Lin | 2020 | 76 | 61 | 80 | 51 | [64] |
Zheng | 2020 | 53 | 53 [c] | NA | 47 | [65] |
Baroncelli | 2021 | 24 | 24 | 100 | NR | [66] |
Ishihara | 2021 | 28 | 28 [c] | NA | 23 | [67] |
Jiménez | 2021 | 17 | 17 | 100 | 16 | [68] |
Lin | 2021 | 105 | 105 [c] | NA | 88 | [69] |
Park | 2021 | 50 | 47 | 94 | 48 | [70] |
Rodríguez-Rubio | 2021 | 39 | 39 [c] | 83 | NR | [71] |
Author | Year | Subject (Male, Female) | Analyzed Phenotype | p Value | Reference |
---|---|---|---|---|---|
Whyte | 1996 | 30 (7, 23) | serum Pi | 0.34 | [94] |
serum ionized Ca | 0.89 | ||||
serum Ca | 0.99 | ||||
serum Ca2+×Pi | 0.30 | ||||
serum ALP | 0.075 | ||||
serum iPTH | 0.91 | ||||
urinary Ca/Cr | 0.65 | ||||
urinary Pi/Cr | 0.51 | ||||
% TRP | 0.79 | ||||
Tmp/GFR | 0.59 | ||||
27 (9, 18) | height z-score | 0.11 | |||
Holm | 2001 | 76 (26, 50) | skeletal severity | 0.145 | [37] |
60 (19, 41) | dental severity | 0.272 | |||
Cho | 2005 | 8 (3, 5) | biochemical parameters skeletal severity dental severity | n.s. | [39] |
Song | 2007 | 9 (1, 8) | no description | n.s. | [40] |
Morey | 2011 | 46 (11, 35) | nephrocalcinosis | 0.03 | [44] |
Quinlan | 2012 | 23 (11, 12) | height z-score | n.s. | [47] |
Zhang | 2019 | 139 (46, 93) | serum Pi | 0.251 | [63] |
174 (60, 114) | onset age for any signs | 0.284 | |||
150 (55, 95) | age for first walking | 0.844 | |||
124 (46, 78) | onset age for lower limb deformity | 0.817 | |||
164 (59, 108) | height z-score | 0.094 | |||
47 (19, 28) | RSS | 0.850 | |||
230 (72, 158) | serum i-FGF23 | 0.696 | |||
Ishihara | 2021 | 26 (5, 21) | RSS | 0.11 | [67] |
24 (4, 20) | serum iFGF23 | 0.54 | |||
29 (6, 23) | height z-score | 0.23 | |||
29 (6, 23) | serum phosphate | 0.47 | |||
28 (5, 23) | serum ALP | 0.048 | |||
27 (7, 23) | Tmp/GFR | 0.47 | |||
Rodríguez-Rubio | 2021 | 48 (15, 33) | clinical manifestation growth impairment biochemical parameters | n.s. | [71] |
Author | Year | Subject (N Terminal, C Terminal) | Analyzed Phenotype | p Value | Reference |
---|---|---|---|---|---|
Holm | 2001 | 23, 6 | skeletal severity | 1.000 | [37] |
22, 5 | dental severity | 0.621 | |||
Song | 2007 | 2, 7 | onset age | n.s. | [40] |
skeletal severity | 0.083 | ||||
dental severity | n.s. | ||||
Zhang | 2019 | 113, 26 | serum Pi | 0.573 | [63] |
141, 33 | onset age for any signs | 0.015 | |||
119, 31 | age for first walking | 0.478 | |||
104, 20 | onset age for lower limb deformity | 0.055 | |||
132, 25 | height z-score | 0.692 | |||
37, 10 | RSS | 0.711 | |||
187, 46 | serum i-FGF23 | 0.045 | |||
Baroncelli | 2021 | 24 [a] | dental severity | n.s. | [66] |
height z-score | |||||
skeletal severity | |||||
biochemical parameters | |||||
Lin | 2021 | 105, 24 | onset age | 0.360 | [69] |
height z-score | 0.759 | ||||
serum Pi | 0.286 | ||||
serum ALP | 0.077 | ||||
serum i-FGF23 | 0.485 | ||||
RSS | 0.538 |
Author | Year | Subject (Truncating, Non-Truncating) | Analyzed Phenotype | p Value | Reference |
---|---|---|---|---|---|
Holm | 2001 | 21, 8 | skeletal severity | 0.112 | [37] |
20, 7 | dental severity | 1.000 | |||
Cho | 2005 | 5, 3 | biochemical parameters | n.s. | [39] |
skeletal severity | |||||
dental severity | |||||
Song | 2007 | 3, 6 | onset age | n.s. | [40] |
skeletal severity | |||||
dental severity | |||||
Morey | 2011 | 28, 6 | onset age | 0.08 | [44] |
24, 6 | height z-score | 0.11 | |||
24, 6 | serum Pi | 0.53 | |||
22, 5 | % TRP | 0.028 | |||
16, 6 | 1,25(OH)2D | 0.013 | |||
14, 6 | 25(OH)D | 0.30 | |||
20, 6 | serum PTH | 0.06 | |||
22, 6 | serum ALP | 0.48 | |||
Rafaelsen | 2016 | 21 [a] | height z-score | n.s. | [55] |
skeletal severity | |||||
dental severity | |||||
Zhang | 2019 | 107, 32 | serum Pi | 0.674 | [63] |
143, 31 | onset age for any signs | 0.641 | |||
121, 29 | age for first walking | 0.235 | |||
106, 18 | onset age for lower limb deformity | 0.312 | |||
133, 34 | height z-score | 0.379 | |||
42, 5 | RSS | 0.724 | |||
184, 49 | serum i-FGF23 | 0.777 | |||
Zheng | 2020 | 39, 14 | height z-score | 0.42 | [65] |
39, 14 | serum Pi | 0.94 | |||
38, 13 | Tmp/GFR | 0.42 | |||
39, 14 | serum ALP | 0.37 | |||
Park | 2021 | 39, 9 [a] | onset age | 0.561 | [70] |
height z-score | 0.793 | ||||
serum Pi | 0.672 | ||||
serum Ca | 0.750 | ||||
serum ALP | 0.916 | ||||
serum 25(OH)D | 0.023 | ||||
serum PTH | 0.235 | ||||
%TRP | 0.362 | ||||
Tmp/GFR | 0.362 | ||||
urine Ca/Cr | 0.644 | ||||
Baroncelli | 2021 | 24 [b] | dental severity | n.s. | [66] |
height z-score | |||||
skeletal severity | |||||
biochemical parameters | |||||
Jiménez | 2021 | 17 [b] | height z-score | <0.05 | [68] |
onset age | n.s. | ||||
serum i-FGF23 | n.s. | ||||
skeletal severity | n.s. | ||||
Ishihara | 2021 | 21, 4 | RSS | 0.53 | [67] |
19, 4 | serum i-FGF23 | 0.60 | |||
22, 6 | height z-score | 0.29 | |||
22, 6 | serum Pi | 0.25 | |||
21, 6 | serum ALP | 0.49 | |||
21, 5 | Tmp/GFR | 0.35 | |||
Lin | 2021 | 124, 29 | onset age | 0.996 | [69] |
height z-score | 0.510 | ||||
serum Pi | 0.925 | ||||
serum ALP | 0.700 | ||||
serum i-FGF23 | 0.695 | ||||
RSS | 0.895 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ohata, Y.; Ishihara, Y. Pathogenic Variants of the PHEX Gene. Endocrines 2022, 3, 498-511. https://doi.org/10.3390/endocrines3030040
Ohata Y, Ishihara Y. Pathogenic Variants of the PHEX Gene. Endocrines. 2022; 3(3):498-511. https://doi.org/10.3390/endocrines3030040
Chicago/Turabian StyleOhata, Yasuhisa, and Yasuki Ishihara. 2022. "Pathogenic Variants of the PHEX Gene" Endocrines 3, no. 3: 498-511. https://doi.org/10.3390/endocrines3030040